Stock Events

Stock Events

Medexus Pharmaceuticals 

$0
17
+$0+0% Monday 00:00

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
0
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
Jul 25
$0
Jan 25
$0
Jul 24
$0
Jan 24
$0
Jul 23
$0
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

21JunExpected
Q2 2018
Q3 2018
Q4 2018
Q2 2019
Q3 2019
Q4 2019
Q1 2020
-0.61
-0.39
-0.18
0.04
Expected EPS
-0.09
Actual EPS
-0.15

Financials

1.84%Profit Margin
Profitable
2017
2018
2019
2020
2021
2022
1.55BRevenue
28.64MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PDDPF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Jazz Pharmaceuticals
JAZZ
Mkt Cap8.35B
Jazz Pharmaceuticals has a diverse portfolio in areas like oncology and pain management, overlapping with Medexus's treatment offerings.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie competes in the immunology and oncology sectors, directly challenging Medexus's product lines.
AMGEN
AMGN
Mkt Cap160.66B
Amgen's focus on biologics in areas like rheumatology and oncology puts it in direct competition with Medexus's treatments.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a broad product range that includes treatments in areas competing with Medexus, such as rheumatology.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb's involvement in immunology and oncology treatments makes it a competitor to Medexus's product offerings.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences' focus on innovative therapies in areas like oncology and inflammatory diseases competes with Medexus's portfolio.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, known for its innovative biologics in areas like immunology, competes with Medexus's therapeutic areas.
Novo Nordisk
NVO
Mkt Cap217.54B
Novo Nordisk's products in chronic disease management, such as hemophilia treatments, place it in competition with Medexus.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals' focus on serious chronic diseases, including cystic fibrosis, competes with Medexus's approach to chronic conditions.

About

Pharmaceuticals: Other
Health Technology
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.
Show more...
CEO
Kenneth d’Entremont
Country
CA
ISIN
CA58410Q2036

Listings

F
DE
P731.F
TO
CA
MDP.TO
OTC Link
US
MEDXF

0 Comments

Share your thoughts

FAQ

What is Medexus Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Medexus Pharmaceuticals stocks are traded under the ticker PDDPF.
What were Medexus Pharmaceuticals earnings last quarter?▼
PDDPF earnings for the last quarter are -0.15 USD per share, whereas the estimation was -0.09 USD resulting in a -66.67% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Medexus Pharmaceuticals revenue for the last year?▼
Medexus Pharmaceuticals revenue for the last year amounts to 1.55B USD.
What is Medexus Pharmaceuticals net income for the last year?▼
PDDPF net income for the last year is 28.64M USD.
Does Medexus Pharmaceuticals pay dividends?▼
Yes, PDDPF dividends are paid semi-annual. The last dividend per share was 0 USD. As of today, Dividend Yield (FWD)% is 0%.
In which sector is Medexus Pharmaceuticals located?▼
Medexus Pharmaceuticals operates in the Healthcare sector.
When did Medexus Pharmaceuticals complete a stock split?▼
The last stock split for Medexus Pharmaceuticals was on December 19, 2018 with a ratio of 1:15.
Where is Medexus Pharmaceuticals headquartered?▼
Medexus Pharmaceuticals is headquartered in Verdun, CA.